Irinotecan
Neoplasm of Bone
Actuate Therapeutics Inc.Small moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Neoplasm of Bone cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zoledronate AstraZeneca | Phase 4 | BB |
Pregabalin Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 4 | BB |
azd0530 AstraZeneca | Phase 2 | B |
GEMOGENOVATUCEL-T Gradalis, Inc. | Phase 3 | B |
Lomustine Actuate Therapeutics Inc. | Phase 2 | CCC |
View all 16 →
Same molecule, other indications
Irinotecan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →